A biomarker study for atezolizumab in patients with relapsed/refractory NK/T-cell lymphoma (ATTACK)

An exploratory biomarker study in an investigator initiated phase II trial of atezolizumab in patients with relapsed/refractory NK/T-cell lymphoma - An exploratory biomarker study in an investigator initiated phase II trial of atezolizumab in patients with relapsed/refractory NK/T-cell lymphoma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000039968

Enrollment

Registered

2020-03-28

Start date

2020-03-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

extranodal NK/T-cell lymphoma, nasal type (ENKL)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients enrolled in the NCCH1903 study who agree with the content of this biomarker study and submit the written consent form

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
1. Gene alterations by targeted DNA sequence 2. Gene expression and fusion genes by targeted RNA sequence 3. Positive rate of PD-1, PD-L1, and PD-L2 by histopathological evaluation	—

Secondary

Measure	Time frame
1. Gene alterations and expressions by whole exome, whole genome, and RNA sequence 2. Gene expressions, TCR/BCR repertoires, surface markers, and antigen specificity by ingle cell analysis 3. Gene and surface marker expressions using preserved peripheral blood samples	—

Countries

Japan

Contacts

Public ContactJunji Koya

National Cancer Center Research Institute, Division of Molecular Oncology

jkoya@ncc.go.jp03-3542-2511

Outcome results